{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:40:49Z","timestamp":1794508849010,"version":"4.9.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["2P30DK089507"],"award-info":[{"award-number":["2P30DK089507"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["000527CC319"],"award-info":[{"award-number":["000527CC319"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["2P30DK089507"],"award-info":[{"award-number":["2P30DK089507"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["000527CC319"],"award-info":[{"award-number":["000527CC319"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Evaluating approaches to reduce treatment burden is a research priority among people with cystic fibrosis on highly effective modulators, including elexacaftor-tezacaftor-ivacaftor (ETI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to evaluate the impact of discontinuing both hypertonic saline (HS) and dornase alfa (DA) versus continuing both therapies among a subgroup of participants in the SIMPLIFY study who sequentially participated in trials evaluating the independent clinical effects of discontinuing HS and DA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SIMPLIFY participants \u226512 years old on ETI and constituting a subgroup using both HS and DA at study entry were randomized to the HS or DA trial and then randomized 1:1 to continue or discontinue the applicable therapy for 6 weeks. After completion of the first trial, eligible participants could enroll in the second trial beginning with a 2-week run-in. Study outcomes were compared across the duration of SIMPLIFY participation between a cohort remaining on both therapies during SIMPLIFY and a cohort that sequentially discontinued both as a result of trial randomizations. Multivariable regression models were used to estimate treatment differences, adjusted for time between trials, trial order, baseline age, sex at birth, and percent predicted forced expiratory volume in 1 second (ppFEV1) at study entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-three participants discontinued both therapies by the end of SIMPLIFY, and 63 remained on both, with overall average ppFEV1 of 96.7% at study entry and 3.9 months as the average duration of follow-up from beginning of the first trial to completion of the second trial, including time between trials. No clinically meaningful difference in the change in ppFEV1 from baseline to completion of the second trial was observed between those who discontinued and those who remained on both therapies (difference: 0.22% off-on; 95% confidence interval\u2009=\u2009\u22121.60, 2.03). Changes in lung clearance index at 2.5% starting concentration, patient-reported outcomes, and safety outcomes were also comparable. Patient-reported treatment burden, as measured by a Cystic Fibrosis Questionnaire\u2013Revised subscale, significantly decreased in those who discontinued both therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SIMPLIFY participants who sequentially discontinued both HS and DA experienced no meaningful changes in clinical outcomes and reported decreased treatment burden as compared with those who remained on both therapies. These data continue to inform a new era of postmodulator care of people with cystic fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202404-366oc","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T09:31:11Z","timestamp":1721727071000},"page":"1507-1515","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis"],"prefix":"10.1093","volume":"21","author":[{"given":"Nicole","family":"Mayer-Hamblett","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington"},{"name":"Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Gifford","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio"},{"name":"Rainbow Babies and Children\u2019s Hospital, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Kloster","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Russell","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-6350","authenticated-orcid":false,"given":"Andrew T.","family":"Braun","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Gibson","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington"},{"name":"Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana E.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel W.","family":"Linnemann","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4847","authenticated-orcid":false,"given":"Theodore G.","family":"Liou","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerimiah","family":"Lysinger","sequence":"additional","affiliation":[{"name":"Billings Clinic Pediatric Center, Billings, Montana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Milla","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Riekert","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Young","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7960","authenticated-orcid":false,"given":"David","family":"Nichols","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington"},{"name":"Cystic Fibrosis Foundation, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2026012203190494900_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012203190494900_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"2026012203190494900_bib4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib5","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/S2213-2600(23)00223-0","article-title":"Reducing treatment burden in the era of CFTR modulators","volume":"11","author":"Robinson","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012203190494900_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012203190494900_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"2026012203190494900_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0140-6736(93)92297-7","article-title":"Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis","volume":"342","author":"Ranasinha","year":"1993","journal-title":"Lancet"},{"key":"2026012203190494900_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0022-3476(97)70134-3","article-title":"Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis","volume":"131","author":"Eisenberg","year":"1997","journal-title":"J Pediatr"},{"key":"2026012203190494900_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/thx.50.4.333","article-title":"Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I","volume":"50","author":"Shah","year":"1995","journal-title":"Thorax"},{"key":"2026012203190494900_bib11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"J Pediatr"},{"key":"2026012203190494900_bib12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1183\/09031936.00072510","article-title":"The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis","volume":"37","author":"Amin","year":"2011","journal-title":"Eur Respir J"},{"key":"2026012203190494900_bib13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jcf.2021.02.004","article-title":"Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis","volume":"20","author":"Voldby","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012203190494900_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203190494900_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/thx.2009.125831","article-title":"Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function","volume":"65","author":"Amin","year":"2010","journal-title":"Thorax"},{"key":"2026012203190494900_bib17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jcf.2020.07.009","article-title":"A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes","volume":"19","author":"Donaldson","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M","article-title":"Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis","volume":"21","author":"Eng","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"2026012203190494900_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcf.2023.03.018","article-title":"Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: a retrospective review","volume":"23","author":"Guenther","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2023.05.001","article-title":"Use of cystic fibrosis inhaled medication before and after elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"23","author":"Manika","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib21","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1016\/S1569-1993(23)01532-1","article-title":"610 Clinical features associated with changes in chronic daily therapies in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor: results from the Home Reported Outcomes 2 study","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"Suppl. 2","key":"2026012203190494900_bib22","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S1569-1993(23)00488-5","article-title":"P113 Home reported outcomes (HERO-2) in people with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor: self-reported changes in use of chronic daily therapies at enrolment","volume":"22","author":"Ren","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203190494900_bib24","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1569-1993(23)01041-X","article-title":"Impact of discontinuing both hypertonic saline and dornase alfa in people with CF established on elexacaftor\/tezacaftor\/ivacaftor: a SIMPLIFY ancillary study","volume":"22","author":"Hamblett","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib25","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026012203190494900_bib26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11136-011-0036-z","article-title":"Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample","volume":"21","author":"Quittner","year":"2012","journal-title":"Qual Life Res"},{"key":"2026012203190494900_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","article-title":"Patient-reported respiratory symptoms in cystic fibrosis","volume":"8","author":"Goss","year":"2009","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2020.07.008","article-title":"Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203190494900_bib29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"2026012203190494900_bib30","first-page":"295","article-title":"Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS","volume":"48","author":"Goss","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2026012203190494900_bib31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2213-2600(21)00546-4","article-title":"The effect of inhaled hypertonic saline on lung structure in children aged 3\u20136 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial","volume":"10","author":"Tiddens","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026012203190494900_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1513\/AnnalsATS.202308-735RL","article-title":"Assessing safety of discontinuing hypertonic saline in those with lower forced expiratory volume in 1 second after elexacaftor\/tezacaftor\/ivacaftor","volume":"21","author":"Nichols","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203190494900_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012203190494900_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3310\/nihropenres.13260.1","article-title":"Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis [version 1; peer review: 2 approved]","volume":"2","author":"Altabee","year":"2022","journal-title":"NIHR Open Res"},{"key":"2026012203190494900_bib35","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"key":"2026012203190494900_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1507\/66014315\/annalsats_21_11_1507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1507\/66014315\/annalsats_21_11_1507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:19:36Z","timestamp":1769069976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/11\/1507\/8380784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202404-366oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"2024-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}